Highlights

  • Net sales for the quarter ended July 3, 2026 were $582,782 thousand, and the net loss was $1,036 thousand.
  • Gross profit was $359,249 thousand, operating income was $17,413 thousand, and non-GAAP Adjusted EBITDA was $104.3 million.
  • Reconstructive net sales were $294.5 million, and Prevention & Recovery net sales were $288.2 million for the quarter.
  • Cash and cash equivalents were $12.6 million at July 3, 2026, and $942 million was available on the revolver.

Enovis Corporation (NYSE: ENOV) shares were trading at USD 21.50 on October 27, 2026, up 1.61%, with a relative volume at time of 2.30. The medical technology company received $7.7 million of 2025 tariff refunds in the quarter, recognized a $5.7 million gain on settlement of acquisition contingent consideration, and filed its Form 10-Q for the quarter ended July 3, 2026 on August 6.

Enovis is a Delaware corporation with principal executive offices at 2900 Lake Vista Drive in Lewisville, Texas. It conducts operations through two segments. Prevention & Recovery provides orthopedic devices, software and services from injury prevention through rehabilitation, under brands including Donjoy, Aircast and Chattanooga. Reconstructive offers implants, instrumentation and enabling technologies for hip, knee, shoulder and extremity procedures. The company has production facilities in North America, Europe, North Africa and Asia. Its fiscal year ends December 31.

Second Quarter 2026 Results

The results below are unaudited and cover the three months ended July 3, 2026. Net sales were $582,782 thousand, compared with $564,545 thousand. Gross profit was $359,249 thousand, a gross profit margin of 61.6 percent, compared with 59.3 percent.

Operating income was $17,413 thousand, compared with an operating loss of $16,796 thousand. Income tax expense was $8,501 thousand. The company reported a net loss of $1,036 thousand, compared with a net loss of $36,548 thousand. Net loss attributable to Enovis Corporation was $1,190 thousand, or $0.02 per share, compared with $0.64 per share.

Adjusted EBITDA, a non-GAAP measure, was $104.3 million, an Adjusted EBITDA margin of 17.9 percent, compared with $91.2 million and 16.2 percent. For the six months, net sales were $1,171,933 thousand and the net loss was $9,486 thousand.

Segment Results

Reconstructive net sales were $294.5 million, compared with $274.0 million, with operating income of $2.3 million compared with an operating loss of $26.1 million. Segment Adjusted EBITDA was $54.0 million. The company said existing business sales in Reconstructive rose on higher volumes and that the prior-year period included a $10.0 million purchase of royalty interest.

Prevention & Recovery net sales were $288.2 million, compared with $290.6 million, with operating income of $15.1 million and Adjusted EBITDA of $50.3 million. The company said the October 2025 sale of its Dr. Comfort Footcare Solutions U.S. operations reduced sales by $14.4 million in the quarter.

Debt, Cash Flow and Capital

Total debt was $1,284,508 thousand at July 3, 2026, including a term loan, a $1.1 billion revolving credit facility maturing December 8, 2030, and $460 million of 3.875 percent convertible notes due October 15, 2028. Interest expense, net, was $8,038 thousand for the quarter. Covenants require a maximum senior secured leverage ratio of 3.50:1.00 and a minimum interest coverage ratio of 3.00:1.00.

For the six months, net cash provided by operating activities was $99.0 million, compared with $46.2 million, and purchases of property, plant and equipment and intangibles were $96.7 million. Net debt repayments were $15.0 million. Cash and cash equivalents were $12.6 million, down $23.8 million from $36.4 million at December 31, 2025. The remaining stock repurchase authorization was $100 million, and no repurchases have been made under the plan since the third quarter of 2018.

Outlook and Disclosed Risks

The filing does not provide numerical guidance. It states that the company believes its sources of liquidity are adequate to fund operations for the next twelve months and that sales in both segments typically peak in the fourth quarter. It lists risks including indebtedness, integration of the Lima Acquisition, tariffs, restructuring activities, and the possibility of impairment of intangible assets or goodwill. The company also recorded an increase in valuation allowance on U.S. deferred tax assets.